Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study
Abstract Objective While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab. This study evaluated the tolerability of switching from erenumab to fremanezumab in patient...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10194-025-02087-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849334262068674560 |
|---|---|
| author | Faisal Mohammad Amin Thor Linnet Christopher Kjaer Cullum Thien Phu Do Samaira Younis |
| author_facet | Faisal Mohammad Amin Thor Linnet Christopher Kjaer Cullum Thien Phu Do Samaira Younis |
| author_sort | Faisal Mohammad Amin |
| collection | DOAJ |
| description | Abstract Objective While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab. This study evaluated the tolerability of switching from erenumab to fremanezumab in patients with chronic migraine who experienced adverse events on erenumab. Methods Data was obtained from adult patients with chronic migraine who failed erenumab treatment due to lack of tolerability and subsequently received at least three months of treatment with fremanezumab after discontinuing erenumab. Adverse events were recorded before and after the switch. Results In total, 94 patients were enrolled, with a median age of 50 years. Hereof, 29 (31%) participants experienced treatment-emergent adverse events during the study period after switching from erenumab to fremanezumab. The most prevalent adverse event on erenumab before switching was constipation (n = 74, 79%), which reduced to only 12% (n = 9) of patients who switched to fremanezumab. There was no treatment discontinuation after switching to fremanezumab during the three-months study period. Conclusion Switching treatment from erenumab to fremanezumab due to adverse events is well-tolerated in patients with chronic migraine. This findings suggests a viable option to switch between treatments. Further studies are needed to assess the efficacy of switching between these treatments. |
| format | Article |
| id | doaj-art-a29e9118bc0f44caac2ec8beb9ec6322 |
| institution | Kabale University |
| issn | 1129-2377 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | The Journal of Headache and Pain |
| spelling | doaj-art-a29e9118bc0f44caac2ec8beb9ec63222025-08-20T03:45:36ZengBMCThe Journal of Headache and Pain1129-23772025-07-012611710.1186/s10194-025-02087-zTolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational studyFaisal Mohammad Amin0Thor Linnet1Christopher Kjaer Cullum2Thien Phu Do3Samaira Younis4Department of Neurology, Danish Headache Center, Copenhagen University Hospital– RigshospitaletDepartment of Neurology, Danish Headache Center, Copenhagen University Hospital– RigshospitaletDepartment of Neurology, Danish Headache Center, Copenhagen University Hospital– RigshospitaletDepartment of Neurology, Danish Headache Center, Copenhagen University Hospital– RigshospitaletDepartment of Neurology, Danish Headache Center, Copenhagen University Hospital– RigshospitaletAbstract Objective While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab. This study evaluated the tolerability of switching from erenumab to fremanezumab in patients with chronic migraine who experienced adverse events on erenumab. Methods Data was obtained from adult patients with chronic migraine who failed erenumab treatment due to lack of tolerability and subsequently received at least three months of treatment with fremanezumab after discontinuing erenumab. Adverse events were recorded before and after the switch. Results In total, 94 patients were enrolled, with a median age of 50 years. Hereof, 29 (31%) participants experienced treatment-emergent adverse events during the study period after switching from erenumab to fremanezumab. The most prevalent adverse event on erenumab before switching was constipation (n = 74, 79%), which reduced to only 12% (n = 9) of patients who switched to fremanezumab. There was no treatment discontinuation after switching to fremanezumab during the three-months study period. Conclusion Switching treatment from erenumab to fremanezumab due to adverse events is well-tolerated in patients with chronic migraine. This findings suggests a viable option to switch between treatments. Further studies are needed to assess the efficacy of switching between these treatments.https://doi.org/10.1186/s10194-025-02087-zCalcitonin gene-related peptideCGRPHeadacheConstipationGastrointestinal symptomsMigraine with aura |
| spellingShingle | Faisal Mohammad Amin Thor Linnet Christopher Kjaer Cullum Thien Phu Do Samaira Younis Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study The Journal of Headache and Pain Calcitonin gene-related peptide CGRP Headache Constipation Gastrointestinal symptoms Migraine with aura |
| title | Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study |
| title_full | Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study |
| title_fullStr | Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study |
| title_full_unstemmed | Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study |
| title_short | Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study |
| title_sort | tolerability of switch from erenumab to fremanezumab in adults with chronic migraine a 3 month single center prospective real world observational study |
| topic | Calcitonin gene-related peptide CGRP Headache Constipation Gastrointestinal symptoms Migraine with aura |
| url | https://doi.org/10.1186/s10194-025-02087-z |
| work_keys_str_mv | AT faisalmohammadamin tolerabilityofswitchfromerenumabtofremanezumabinadultswithchronicmigrainea3monthsinglecenterprospectiverealworldobservationalstudy AT thorlinnet tolerabilityofswitchfromerenumabtofremanezumabinadultswithchronicmigrainea3monthsinglecenterprospectiverealworldobservationalstudy AT christopherkjaercullum tolerabilityofswitchfromerenumabtofremanezumabinadultswithchronicmigrainea3monthsinglecenterprospectiverealworldobservationalstudy AT thienphudo tolerabilityofswitchfromerenumabtofremanezumabinadultswithchronicmigrainea3monthsinglecenterprospectiverealworldobservationalstudy AT samairayounis tolerabilityofswitchfromerenumabtofremanezumabinadultswithchronicmigrainea3monthsinglecenterprospectiverealworldobservationalstudy |